Welcome to CarDekho. CAR T-cell therapy is an advanced form of cancer immunotherapy that uses a patient’s own immune cells to recognize and attack certain cancer cells. Doctors collect T cells from the blood, modify them in a laboratory, and return the modified cells to the patient through an infusion. This personalized approach is mainly used for certain blood cancers.
Unlike many traditional treatments, CAR T-cell therapy changes immune cells so they can recognize a specific target on cancer cells. It can produce strong and sometimes long-lasting responses in some patients, but it also has serious risks and is not suitable for every cancer or patient.
What Is CAR T-Cell Therapy?
CAR T-cell therapy stands for chimeric antigen receptor T-cell therapy. It is a form of cell-based immunotherapy that uses a patient’s own T cells. These immune cells are collected from the blood and genetically modified in a laboratory so they can recognize a specific target found on certain cancer cells. After the modified cells are returned to the body, they can identify and attack cells carrying that target. This makes the treatment a personalized approach for selected cancers.
What Does CAR T Mean?
CAR means chimeric antigen receptor, a specially designed receptor added to the surface of a T cell. T cells naturally help the immune system find and remove harmful or abnormal cells, but cancer cells can sometimes avoid normal immune detection. Adding a CAR gives these T cells a new way to recognize a particular cancer-related antigen.
The engineered T cells are then able to identify their intended target more precisely. The CAR works like a recognition system, helping the immune cell find cells that carry the matching antigen. Because different cancers can have different targets, the CAR design and treatment approach depend on the patient’s specific cancer.
How CAR T Cells Fight Cancer
The process starts by collecting T cells from the patient’s blood. Scientists then modify the cells to produce the CAR receptor and grow them in the laboratory until enough cells are available for treatment. After careful preparation and testing, the modified cells are infused back into the patient’s bloodstream.
Once inside the body, CAR T cells search for cells carrying their specific target antigen. When they find and bind to that target, the cells become activated and can destroy the targeted cancer cells. The target varies according to the cancer and CAR T product, which is why CAR T-cell therapy is currently used for specific cancers rather than as a treatment for every cancer type.
Which Cancers Can CAR T-Cell Therapy Treat?
Current CAR T-cell therapy is mainly used to treat certain blood cancers, particularly cancers involving B cells or plasma cells. Its approved uses are not the same for every treatment product or country. Doctors consider the patient’s cancer type, age, previous treatments, disease status, and the specific CAR T product available before recommending this therapy. This means having a blood cancer does not automatically make someone eligible for CAR T treatment.
Blood Cancers Treated With CAR T Therapy
CAR T treatments have been approved for selected cases of:
- B-cell acute lymphoblastic leukemia
- Certain types of non-Hodgkin lymphoma
- Large B-cell lymphomas
- Follicular lymphoma
- Mantle cell lymphoma
- Multiple myeloma
The exact use depends on the patient’s cancer and the approved indication of the specific CAR T product. Many treatments are designed to recognize proteins found on particular cancer cells. For example, CD19 is a common target in several B-cell cancers, while BCMA is targeted by some CAR T treatments for multiple myeloma.
Can CAR T Therapy Treat Solid Tumors?
Researchers are studying CAR T-cell therapy for solid tumors, including some brain and breast cancers. However, treating solid tumors is more difficult because cancer cells may not have a target that is unique enough to attack without affecting healthy tissue. The tumor environment can also make it harder for CAR T cells to reach the cancer and remain active.
Because of these challenges, many CAR T approaches for solid tumors are still being investigated in clinical research. They should not be confused with established CAR T treatments that are already approved for certain blood cancers. The availability of these experimental treatments depends on ongoing studies and local regulations.
How Does CAR T-Cell Therapy Work?
The CAR T-cell therapy process follows several controlled steps, starting with a medical assessment and ending with cell infusion and close monitoring. The complete timeline can vary based on the patient’s condition, the treatment center, the manufacturing method, and the specific CAR T product being used. Each stage is important because the therapy is individually prepared and can cause serious side effects.
Step 1: Medical Evaluation
Before treatment, doctors review the patient’s cancer diagnosis, previous treatments, current disease status, and general health. Blood tests and other assessments may be performed to check whether the patient can safely undergo the treatment.
The medical team also checks whether the cancer carries the specific antigen that the planned CAR T cells are designed to recognize. This evaluation helps doctors determine whether the treatment is appropriate and identify possible risks before therapy begins.
Step 2: T-Cell Collection
The patient’s blood is collected through a process called leukapheresis. A special machine separates white blood cells, including T cells, from the blood while most other blood components are returned to the patient.
The collected T cells become the starting material for the personalized treatment. They are carefully prepared and sent for the next stage, where they will be genetically modified to recognize the patient’s cancer.
Step 3: T-Cell Genetic Modification
The collected T cells are modified in a laboratory so they can produce a chimeric antigen receptor (CAR). This receptor is designed to recognize a specific antigen on the target cancer cells.
The CAR contains parts that help the T cell recognize its target and activate after binding to it. The goal is to create engineered immune cells that can find and attack cancer cells carrying the selected antigen.
Step 4: Cell Manufacturing and Testing
After modification, the T cells are grown in the laboratory to produce a sufficient number for treatment. This stage requires controlled conditions because the cells must remain suitable for infusion.
Before the cells are given to the patient, they undergo quality testing for factors such as identity, purity, safety, and potency. The manufacturing process can take several weeks, although the exact timeline varies between treatments and centers.
Step 5: Preparing the Body for CAR T Cells
Before receiving the engineered cells, patients commonly receive lymphodepleting chemotherapy. This treatment reduces certain immune cells and helps create conditions that allow the infused CAR T cells to expand and function in the body.
The medicines and schedule used for this preparation depend on the treatment plan. It is an important part of the overall CAR T-cell therapy process and is completed before the engineered cells are infused.
Step 6: CAR T-Cell Infusion and Monitoring
The prepared CAR T cells are given back to the patient through an intravenous infusion. The procedure itself is generally similar to receiving other medicines through an IV, but careful medical supervision is required afterward.
The treatment team closely monitors the patient for reactions such as cytokine release syndrome (CRS) and neurological complications. Depending on the patient’s condition and the treatment center’s protocol, hospitalization or close outpatient monitoring may be required.
Read also: Rubicon Car Price In Pakistan, Specs, Features & Guide 2026
Who Can Receive CAR T-Cell Therapy?
Not every cancer patient is suitable for CAR T-cell therapy. Doctors first review the cancer type, treatment history, overall health, and other medical factors to decide whether the therapy is appropriate. Eligibility also depends on whether a suitable CAR T treatment is approved and available for that particular cancer.
Factors Doctors Consider
Important considerations may include:
- Type of cancer
- Specific cancer target or antigen
- Previous cancer treatments
- Whether the disease has returned or resisted treatment
- Overall physical condition
- Blood-cell levels
- Organ function
- Presence of active infections
- Previous treatments and their effects
Doctors also consider whether the patient’s cancer matches the approved use of the available CAR T product. The treatment plan must be suitable for the patient’s medical condition and the resources of the treatment center.
Why Eligibility Varies From Patient to Patient
Two people with the same type of cancer may still have different treatment options. Their cancer biology, previous treatments, disease progression, overall health, or existing medical problems can affect whether CAR T-cell therapy is appropriate.
For this reason, CAR T-cell therapy eligibility cannot be decided through an online checklist. A qualified oncology or cellular-therapy team must review the patient’s complete medical information before recommending treatment.
Benefits of CAR T-Cell Therapy
CAR T-cell therapy offers a different treatment approach for some difficult-to-treat blood cancers. It uses modified immune cells to target cancer more directly and may provide meaningful benefits for selected patients.
Personalized Cancer Treatment
A key feature of CAR T therapy is that many treatments use the patient’s own T cells. These cells are changed in a laboratory so they can recognize a specific target on cancer cells.
This creates a more personalized form of cancer immunotherapy. The treatment is designed around the cancer target and the specific CAR T product being used.
Potential for Long-Lasting Responses
Some patients achieve deep responses after CAR T-cell therapy, and these responses can last for long periods. In certain blood cancers, some people remain without detectable disease after treatment.
However, results are different for each patient. The therapy does not guarantee permanent remission, and cancer may return in some cases.
Treatment Option for Certain Relapsed Cancers
CAR T therapy can offer another treatment option for some patients whose cancer has returned or did not respond well to earlier treatments. It may be considered when standard therapies are no longer effective or suitable.
Doctors base this decision on factors such as cancer type, previous treatments, overall health, and the approved use of the specific CAR T product.
CAR T-Cell Therapy Side Effects and Risks
Although CAR T-cell therapy can help selected patients, it may also cause serious side effects. Because of these risks, patients need close monitoring by medical teams experienced in cellular therapy, especially during the early period after treatment.
Cytokine Release Syndrome
Cytokine release syndrome (CRS) can occur when CAR T cells become active and trigger a strong immune response. Common symptoms include fever, chills, headache, nausea, fast heartbeat, low blood pressure, breathing problems, and severe tiredness.
CRS can be mild or severe. Serious cases may affect the heart, lungs, or other organs and can become life-threatening. Close medical observation helps doctors recognize and manage the condition quickly.
Neurological Side Effects
Immune effector cell-associated neurotoxicity syndrome (ICANS) is another possible complication of CAR T-cell therapy. It can affect how the brain and nervous system function after treatment.
Symptoms may include confusion, difficulty speaking, reduced awareness, tremors, seizures, headache, or balance problems. Patients require prompt assessment if these symptoms appear so the medical team can provide appropriate treatment.
Infection and Low Blood Counts
CAR T treatment can temporarily weaken the immune system and lower blood-cell levels. This may increase the risk of infections and can also cause fatigue, bruising, or bleeding.
Because infections can become serious, doctors may perform regular blood tests and monitor patients closely during recovery. Patients should also report signs of infection or other unusual symptoms without delay.
Other Possible Complications
Other risks may include reactions during infusion, changes in blood mineral levels, and prolonged immune suppression. Some patients may also experience complications related to the chemotherapy or other parts of the treatment process.
Rare cases of secondary T-cell cancers have also been reported after some CAR T-cell therapies. This risk is being monitored by health authorities and should be discussed with the treating team. The type and severity of side effects can vary, so ongoing medical follow-up is important.
CAR T-Cell Therapy Cost
The cost of CAR T-cell therapy can be high because it involves personalized cell collection, laboratory processing, specialized treatment, and careful medical monitoring. The total expense varies depending on the treatment plan, hospital, CAR T product, and patient’s medical needs.
What Determines the Cost?
Several parts of treatment can contribute to the overall cost:
- T-cell collection
- Cell processing and manufacturing
- Laboratory testing
- Lymphodepleting chemotherapy
- CAR T-cell infusion
- Hospital admission
- Medicines
- Blood tests and imaging
- Side-effect management
- Follow-up care
The cost of the CAR T cells is only one part of the total expense. Other medical services, hospital care, medicines, and monitoring can add significantly to the final bill.
CAR T Therapy Cost in Pakistan
There is no fixed CAR T therapy cost in Pakistan for every patient. The total amount can vary based on the treatment center, CAR T product, cell manufacturing process, hospitalization, medicines, testing, and management of complications.
Patients and families should request a written cost estimate from the treatment center. They should confirm which services are included and which expenses may need to be paid separately before starting treatment.
Questions to Ask About Treatment Costs
Before treatment, patients can ask:
- Does the price include T-cell collection?
- Is cell manufacturing included?
- Does it cover chemotherapy before infusion?
- Are hospitalization and monitoring included?
- Are medicines for side effects included?
- What follow-up costs should be expected?
- Which expenses are not included in the quoted price?
CAR T-Cell Therapy in Pakistan
CAR T-cell therapy in Pakistan reached an important milestone in 2026. The Armed Forces Bone Marrow Transplant Centre (AFBMTC) in Rawalpindi reported that it administered Pakistan’s first indigenously prepared anti-CD19 CAR T-cell treatment on June 18, 2026, to a 21-year-old patient with relapsed/refractory B-cell acute lymphoblastic leukemia. The center reported that the patient achieved MRD-negative complete remission by Day +14. Radio Pakistan also reported the first-ever CAR T-cell therapy procedure in the country.
Current Development of CAR T Therapy in Pakistan
The first reported treatment was carried out at AFBMTC in Rawalpindi using locally prepared anti-CD19 CAR T cells. According to the center, the patient had relapsed twice before receiving the treatment and was later discharged on July 3, 2026.
This development shows that advanced cellular therapy is now being performed in Pakistan. However, access is still specific to available treatment programs, cancer type, patient eligibility, and medical resources. Patients should confirm current treatment availability directly with a qualified medical center.
What Patients Should Know Before Seeking Treatment
Anyone considering CAR T therapy should first consult a qualified hematologist, oncologist, or cellular-therapy specialist. Before making treatment arrangements, patients should confirm:
- Whether their cancer is a suitable target
- Whether they meet current eligibility requirements
- Which CAR T treatment is available
- How the cells will be manufactured
- Expected treatment and monitoring time
- Where follow-up care will take place
- What the total cost includes
Patients should also be careful with online claims about guaranteed cures or immediate treatment access. A qualified medical team should provide the final guidance based on the patient’s individual condition.
What to Expect Before and After CAR T Therapy
CAR T-cell therapy involves several stages beyond the cell infusion. Patients may need medical testing, T-cell collection, treatment preparation, close monitoring, and follow-up care. Understanding these steps can help patients and families plan for the treatment period and recovery.
Before Treatment
Before CAR T-cell therapy, doctors review the patient’s cancer history, overall health, and treatment options. Tests may be performed to confirm eligibility and determine whether the cancer has the target needed for the planned CAR T treatment.
The patient’s T cells are then collected and prepared for manufacturing. Lymphodepleting chemotherapy may be given before the modified cells are infused. Patients may also need to plan for transportation, accommodation, caregiver support, and time away from work or daily activities.
After CAR T-Cell Infusion
After CAR T-cell infusion, the medical team closely watches for complications such as cytokine release syndrome (CRS) and neurological side effects. Monitoring may include regular examinations, blood tests, and checks for signs of infection or other treatment-related problems.
Follow-up also focuses on recovery and the cancer’s response to treatment. Some patients may need to stay in hospital or remain near the treatment center for a period after infusion. Recovery varies between individuals, so patients should return to normal activities only when advised by their treating team.
Questions to Ask Your Doctor About CAR T Therapy
Before starting CAR T-cell therapy, patients and caregivers should understand both the expected benefits and the possible risks.
Useful questions include:
- Am I eligible for CAR T-cell therapy?
- Which CAR T treatment is being considered for me?
- What cancer target does the treatment recognize?
- How long will the complete treatment process take?
- What side effects are most likely in my situation?
- Which symptoms require immediate medical attention?
- How long will I need to stay near the treatment center?
- What will the total treatment cost include?
- What follow-up care will I need?
- Are there other treatment options I should consider?
A clear discussion with the medical team can help patients understand what to expect and prepare for the practical demands of treatment.
Frequently Asked Questions About CAR T-Cell Therapy
Can CAR T-cell therapy be repeated if cancer returns?
In some cases, another CAR T treatment or a different therapy may be considered, but this depends on the cancer, previous treatment, and the patient’s health.
How long can CAR T cells remain in the body?
CAR T cells may remain in the body for months or even longer in some patients. Their persistence varies depending on the treatment and individual immune response.
Can children receive CAR T-cell therapy?
Yes, certain CAR T treatments are used for children with specific cancers. Age requirements depend on the particular CAR T product and its approved use.
Does CAR T-cell therapy require a special diet?
There is no single CAR T-specific diet for everyone. Nutrition plans are usually based on the patient’s condition, treatment effects, and advice from the medical team.
Can CAR T-cell therapy affect daily activities after treatment?
Recovery may temporarily affect work, school, travel, and other normal activities. The timing for returning to regular activities should be decided with the treating team based on recovery and follow-up needs.
Conclusion
CAR T-cell therapy is a specialized form of cancer immunotherapy that changes a patient’s own T cells so they can recognize and attack selected cancer cells. The treatment involves medical evaluation, cell collection, laboratory modification, cell expansion, preparation, chemotherapy, infusion, and careful monitoring.
The therapy has created important options for some people with difficult-to-treat blood cancers, but it also carries serious risks. Treatment eligibility, expected outcomes, side effects, and costs can vary considerably from one patient to another. In Pakistan, the development of locally prepared CAR T treatment represents a new step in advanced cellular therapy. Patients should discuss their individual situation with a qualified oncology or cellular-therapy team before making treatment decisions.
